Carboplatin

Retinoblastoma, advanced Thymoma, Advance Directives + 20 more
Treatment
2 FDA approvals
20 Active Studies for Carboplatin

What is Carboplatin

CarboplatinThe Generic name of this drug
Treatment SummaryCarboplatin is a chemotherapy drug used to treat advanced ovarian cancer. It was first tested in 1982 and was approved by the FDA in 1989. Carboplatin is an analog of cisplatin, but it has fewer side effects such as kidney damage and vomiting.
Carboplatinis the brand name
image of different drug pills on a surface
Carboplatin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Carboplatin
Carboplatin
2004
69

Approved as Treatment by the FDA

Carboplatin, also called Carboplatin, is approved by the FDA for 2 uses including Advanced Ovarian Carcinoma and initial treatment .
Advanced Ovarian Carcinoma
Used to treat Advanced Ovarian Carcinoma in combination with Carboplatin
initial treatment
Used to treat initial treatment in combination with Carboplatin

Effectiveness

How Carboplatin Affects PatientsCarboplatin is a drug used to fight certain types of cancer, particularly ovarian cancer. It takes a few weeks for the drug to become effective, and care must be taken to ensure patients are taking the correct dosage. Patients should be aware that the drug could cause bone marrow suppression and anemia.
How Carboplatin works in the bodyCarboplatin works by directly damaging DNA. It attaches alkyl groups to the nucleotides in the genetic material, causing it to break when repair enzymes attempt to fix it. Additionally, it can form links between two different strands of DNA, preventing them from separating for transcription or replication. Lastly, carboplatin can cause mutations in the DNA.

When to interrupt dosage

The suggested dosage of Carboplatin is based on the diagnosed affliction, including Pharmacotherapy, Carcinoma, Neuroendocrine and advanced Testicular cancer. The measure is contingent upon the technique of issuance, as specified in the table beneath.
Condition
Dosage
Administration
Lymphoma, Non-Hodgkin
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Palliative Treatment
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advanced Cervical Cancer
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Hodgkin Disease
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
melanoma
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Recurrent
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Malignant Mesothelioma
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advanced Head and Neck Cancer
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advanced Sarcoma
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
advanced Thymoma
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advanced Esophageal Cancers
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Metastatic Breast Cancer
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advanced Non Small Cell Lung Cancer (NSCLC)
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advanced Endometrial Cancer
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
conditioning regimens for allogeneic stem cell transplantation therapy
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Advance Directives
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Pharmacotherapy
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Retinoblastoma
, 10.0 mg/mL, 150.0 mg, 150.0 mg/mL, 50.0 mg/mL, 450.0 mg/mL, 15.0 mg/mL, 45.0 mg/mL, 60.0 mg/mL
, Intravenous, Injection, Injection - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Solution, Powder, for solution - Intravenous, Powder, for solution, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

Carboplatin Contraindications
Condition
Risk Level
Notes
Hemorrhage
Do Not Combine
Bone Marrow
Do Not Combine
There are 20 known major drug interactions with Carboplatin.
Common Carboplatin Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Carboplatin is combined with Acteoside.
Carboplatin Toxicity & Overdose RiskSomeone who has overdosed on carboplatin may suffer from low white blood cell levels and liver damage. Treatment should involve relieving symptoms and providing supportive care, such as delaying the next dose.
image of a doctor in a lab doing drug, clinical research

Carboplatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Carboplatin?

148 active clinical trials are currently assessing the potential of Carboplatin to treat Metastatic Breast Cancer, Advance Directives and conditioning regimens for Allogeneic Stem Cell Transplantation Therapy.
Condition
Clinical Trials
Trial Phases
Lymphoma, Non-Hodgkin
0 Actively Recruiting
Metastatic Breast Cancer
95 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1
Advanced Endometrial Cancer
1 Actively Recruiting
Phase 2
Advance Directives
0 Actively Recruiting
Hodgkin Disease
17 Actively Recruiting
Phase 1, Phase 2, Early Phase 1
Advance Directives
0 Actively Recruiting
conditioning regimens for allogeneic stem cell transplantation therapy
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
advanced Thymoma
0 Actively Recruiting
Advanced Sarcoma
1 Actively Recruiting
Phase 1, Phase 2
Palliative Treatment
0 Actively Recruiting
advanced Testicular cancer
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Advanced Esophageal Cancers
0 Actively Recruiting
Advanced Ovarian Carcinoma
11 Actively Recruiting
Phase 1, Phase 2, Early Phase 1, Phase 3, Not Applicable
Recurrent
5 Actively Recruiting
Phase 1, Not Applicable, Phase 2
Advanced Cervical Cancer
0 Actively Recruiting
initial treatment
0 Actively Recruiting
Retinoblastoma
12 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1
Advanced Head and Neck Cancer
1 Actively Recruiting
Phase 2

Carboplatin Reviews: What are patients saying about Carboplatin?

5Patient Review
9/19/2009
Carboplatin for Non-Small Cell Lung Cancer
This drug was better than anticipated. I had no issues with nausea or tiredness, though resting was key. It took a bit longer to get my white blood cell count back up, but a shot of Neulasta helped out a lot.
5Patient Review
4/14/2010
Carboplatin for Cancer of the Ovary
I had eight doses of Taxol starting in 2007, and after a rising CA125, I've now had four more doses. I had a mild allergic reaction to the fourth dose, so I'll be premedicating for the fifth.
5Patient Review
1/9/2009
Carboplatin for Cancer of the Ovary
5Patient Review
4/14/2009
Carboplatin for Cancer of the Ovary
5Patient Review
4/9/2014
Carboplatin for Cancer of the Ovary
I was cancer-free within weeks of starting this treatment, and I couldn't have been more pleased with how easy it was to take.
4.7Patient Review
6/18/2010
Carboplatin for Non-Small Cell Lung Cancer
I was diagnosed with ovarian cancer in 2006 and had three treatments of Taxol and Carboplatin. After CA-125 increased in 2009, I had six treatments. I had an allergic reaction from the carbo during treatment #2. Subsequent treatments included steriods prior to the infusion. I had no nausea at all - fatigue for a few days after then nominally tired. I had Neulasta shots right after my treatments to help with my white blood count.
4.7Patient Review
7/21/2010
Carboplatin for Breast Cancer that has Spread to Another Part of the Body
My mom was diagnosed with stage IV lung cancer in Dec. 09. Carboplatin was one of the chemo drugs used to treat her cancer. After only one treatment, the doctors said that the Carboplatin damaged my mom's kidneys and she passed away on April 22nd.
4.7Patient Review
5/19/2012
Carboplatin for Non-Small Cell Lung Cancer
My husband died as a result of being overmedicated.
4.3Patient Review
11/24/2010
Carboplatin for Breast Cancer that has Spread to Another Part of the Body
This drug, in conjunction with Taxol IV, was part of my chemotherapy treatment post-lung surgery in 2005. I'm pleased to report that I've been cancer-free for over five years now. The treatments made me tired, but I didn't experience any other negative side effects.
4.3Patient Review
3/11/2011
Carboplatin for Non-Small Cell Lung Cancer
It helps me part of the time. I do it with gemzar
4Patient Review
11/18/2009
Carboplatin for Cancer of the Ovary
This drug, in combination with taxol, was incredibly effective. I did have an allergic reaction to the taxol, but by doubling up on steroids, I was able to manage it. The outcome was well worth the side effects!
3.7Patient Review
5/10/2013
Carboplatin for Cancer Involving the Head or Neck
This drug was unfortunately ineffective against my clear cell cancer. I wasted six months because this was the "standard" treatment for endometrial cancer rather than seeking a more targeted approach.
2.3Patient Review
2/14/2011
Carboplatin for Cancer of the Cervix
I've only had two treatments thus far. No serious side effects that I can tell, but it's hard to say if it's truly effective yet or not.
2Patient Review
1/17/2022
Carboplatin for Locally Advanced Breast Carcinoma
One of the less common side effects of this medication is a drastic reduction in blood count. In my case, this happened after the first dose. My doctor lowered the dosage and tried again, but I still needed multiple transfusions. Even after discontinuing use, I'm still anemic and have very low white blood cell and platelet counts 12 months later.
2Patient Review
4/30/2010
Carboplatin for Non-Small Cell Lung Cancer
This was my first time trying this treatment and it didn't work very well for me.
1.7Patient Review
12/27/2012
Carboplatin for Cancer in the Lining of the Uterus
My father was diagnosed with mesotheloma in February 2012 and started chemotherapy soon after. Unfortunately, he had trouble breathing shortly after his first treatment and ended up in the hospital. He is currently on dialysis as a result of kidney failure.
1.7Patient Review
6/6/2012
Carboplatin for Small Cell Cancer of the Lung
I lost a significant amount of hair, but didn't experience any nausea. I've been cancer free for 20 months now.
1Patient Review
9/6/2011
Carboplatin for Non-Small Cell Lung Cancer
My husband has undergone this treatment twice, and so far it's working well the second time around. He didn't lose any hair, which was a big problem last time. Additionally, he hasn't experienced any nausea.
1Patient Review
2/14/2010
Carboplatin for Breast Cancer that has Spread to Another Part of the Body
I experienced some fatigue and nausea with this treatment, but thankfully another drug was able to help with that. I'm now cancer-free four and a half years later.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about carboplatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of chemo is carboplatin?

"Carboplatin is similar to cisplatin but has a platinum atom complexed with glucose.

Carboplatin is a drug that is used to treat cancer. It is classified as an alkylating agent, which are drugs that are used to kill cancer cells. Carboplatin is similar to cisplatin, but it has a platinum atom complexed with glucose."

Answered by AI

Is carboplatin a strong chemo?

"If you experience numbness or tingling, tell your doctor so they can monitor the symptoms. Carboplatin may cause severe tingling in some cases and stopping treatment may be necessary."

Answered by AI

What are the common side effects of carboplatin?

"The symptoms of the illness include nausea, vomiting, diarrhea, constipation, sores in the mouth and throat, pain, burning, or tingling in the hands or feet."

Answered by AI

Is carboplatin an immunotherapy or chemo?

"The standard treatment for this type of cancer generally includes the use of the chemotherapy drugs Paclitaxel and carboplatin."

Answered by AI

Clinical Trials for Carboplatin

Have you considered Carboplatin clinical trials? We made a collection of clinical trials featuring Carboplatin, we think they might fit your search criteria.
Have you considered Carboplatin clinical trials? We made a collection of clinical trials featuring Carboplatin, we think they might fit your search criteria.
Have you considered Carboplatin clinical trials? We made a collection of clinical trials featuring Carboplatin, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top